1.
Br J Haematol
; 201(6): 1033-1046, 2023 06.
Article
in English
| MEDLINE
| ID: mdl-37170397
ABSTRACT
CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti-CD30 CAR-T cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti-CD30 therapies that have emerged to date.
Subject(s)
Hematologic Neoplasms , Immunoconjugates , Adult , Humans , Antibodies, Monoclonal/therapeutic use , Brentuximab Vedotin , Hematologic Neoplasms/drug therapy , Immunoconjugates/therapeutic use , Ki-1 Antigen
2.
Ann Oncol
; 32(10): 1294-1295, 2021 10.
Article
in English
| MEDLINE
| ID: mdl-34171494
Subject(s)
COVID-19 , Neoplasms , Vaccines , BNT162 Vaccine , COVID-19 Vaccines , Humans , Neoplasms/drug therapy , Seroconversion
3.
Ann Oncol
; 32(8): 1051-1053, 2021 08.
Article
in English
| MEDLINE
| ID: mdl-33932501
Subject(s)
COVID-19 , Neoplasms , COVID-19 Vaccines , Humans , Neoplasms/drug therapy , Neoplasms/genetics , RNA, Messenger/genetics , SARS-CoV-2
4.
Ann Oncol
; 29(4): 1065-1066, 2018 04 01.
Article
in English
| MEDLINE
| ID: mdl-29346600